

## Special Issue

# Safety, Efficacy and Optimization of the COVID-19 Vaccines

### Message from the Guest Editor

Among the means of public health intervention, vaccination is both the most effective and cost-effective, with profound implications. The epidemic situation slows down with the emergency use of multiple COVID-19 vaccines; however, the validity of vaccines is being challenged by the constant emergence of new variants. Meanwhile, the safety in mass vaccination remains to be determined because of the short time-on-market of the vaccines. Therefore, there is still a long way to go to extinguish the COVID-19 epidemic. In this Special Issue, we aim to seek a better vaccine design scheme and optimize vaccination strategies by summarizing the influencing factors that impact the safety and efficacy of the different vaccines (inactivated vaccines, adenovirus-vectored vaccines, and nucleic acid vaccines), including design principle, production flow, storage and transportation, vaccination modalities, vaccinated subjects and so on. Multiple types of paper are included in this issue, including articles, reviews, case reports, letters and so on.

### Guest Editor

Dr. Qing Ye

1. The Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China
2. National Clinical Research Center for Child Health, Hangzhou 310052, China
3. National Children's Regional Medical Center, Hangzhou 310052, China

### Deadline for manuscript submissions

closed (30 November 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/127409](https://mdpi.com/si/127409)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).